Effects and mechanism of amyloid β1-42 on mitochondria in astrocytes

Yao,Yunyi; Huang,Jin‑Zhong; Chen,Yingqi; Hu,He‑Juan; Tang,Xiying; Li,Xianhong

doi:10.3892/mmr.2018.8761

Effects and mechanism of amyloid β1-42 on mitochondria in astrocytes

Authors:
- Yunyi Yao
- Jin‑Zhong Huang
- Yingqi Chen
- He‑Juan Hu
- Xiying Tang
- Xianhong Li
View Affiliations

Affiliations: Department of Biochemistry, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China, Department of Neurology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China, Department of Neurology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu 215009, P.R. China, Department of Medical Technology, Suzhou Vocational Health College, Suzhou, Jiangsu 215009, P.R. China
Published online on: March 16, 2018 https://doi.org/10.3892/mmr.2018.8761
Pages: 6997-7004
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Amyloid β (Aβ)1-42 is strongly associated with Alzheimer's disease (AD). The effects of Aβ1‑42 on astrocytes remain largely unknown. The present study focused on the effects of Aβ1‑42 on U87 human glioblastoma cells as astrocytes for in vitro investigation and mouse brains for in vivo investigation. The mechanism and regulation of mitochondria and cytochrome P450 reductase (CPR) were also investigated. As determined by MTT assays, low doses of Aβ1‑42 (<1 µM) marginally promoted astrocytosis compared with the 0 µM group within 24 h, however, after 48 h treatment these doses reduced cellular growth compared with the 0 µM group. Furthermore, Aβ1‑42 doses >5 µM inhibited the growth of U87 cells compared with the 0 µM group after 24 and 48 h treatment. Immunofluorescence analysis demonstrated that astrocytosis was also observed in early stage AD mice compared with wild‑type (WT) mice. In addition, concentrations of Aβ1‑42 were also significantly higher in early stage AD mice compared with WT mice, however, the levels were markedly lower compared with later stage AD mice, as determined by ELISA. In addition to increased levels of Aβ1‑42 in mice with later stage AD, reduced astrocyte staining was observed compared with WT mice. Western blotting indicated that the effect of Aβ1‑42 on U87 cell apoptosis may be regulated via Bcl‑2 and caspase‑3 located in mitochondria, whose functions, including adenosine triphosphate generation, electron transport chain and mitochondrial membrane potential, were inhibited by Aβ1‑42. During this process, the expression and activity of cytochrome P450 reductase was also downregulated. The current study provides novel insight into the effects of Aβ1‑42 on astrocytes and highlights a potential role for astrocytes in the protection against AD.

View Figures

View References

1	Iqbal K and Grundke-Iqbal I: Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci. 64:2234–2244. 2007. View Article : Google Scholar : PubMed/NCBI
2	Awasthi M, Singh S, Pandey VP and Dwivedi UN: Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. J Neurol Sci. 361:256–271. 2016. View Article : Google Scholar : PubMed/NCBI
3	Clark IA and Vissel B: Amyloid β: One of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease. Br J Pharmacol. 172:3714–3727. 2015. View Article : Google Scholar : PubMed/NCBI
4	Blennow K, Mattsson N, Schöll M, Hansson O and Zetterberg H: Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci. 36:297–309. 2015. View Article : Google Scholar : PubMed/NCBI
5	Wang ZX, Tan L, Liu J and Yu JT: The essential role of soluble Aβ oligomers in Alzheimer's disease. Mol Neurobiol. 53:1905–1924. 2016. View Article : Google Scholar : PubMed/NCBI
6	Thal DR, Walter J, Saido TC and Fändrich M: Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease. Acta Neuropathol. 129:167–182. 2015. View Article : Google Scholar : PubMed/NCBI
7	Ebenezer PJ, Weidner AM, LeVine H III, Markesbery WR, Murphy MP, Zhang L, Dasuri K, Fernandez-Kim SO, Bruce-Keller AJ, Gavilán E and Keller JN: Neuron specific toxicity of oligomeric amyloid-β: Role for JUN-kinase and oxidative stress. J Alzheimers Dis. 22:839–848. 2010. View Article : Google Scholar : PubMed/NCBI
8	Bloom GS: Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71:505–508. 2014. View Article : Google Scholar : PubMed/NCBI
9	Drolle E, Hane F, Lee B and Leonenko Z: Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer's disease. Drug Metab Rev. 46:207–223. 2014. View Article : Google Scholar : PubMed/NCBI
10	Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G and Smith MA: Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med. 30:447–450. 2001. View Article : Google Scholar : PubMed/NCBI
11	Liem RK and Messing A: Dysfunctions of neuronal and glial intermediate filaments in disease. J Clin Invest. 119:1814–1824. 2009. View Article : Google Scholar : PubMed/NCBI
12	Tao YQ and Liang GB: Pathologic changes and dysfunctions of astrocytes in the complex rat AD model of ovariectomy combined with D-galactose injection. Bratisl Lek Listy. 115:692–698. 2014.PubMed/NCBI
13	Onyango IG, Dennis J and Khan SM: Mitochondrial dysfunction in Alzheimer's disease and the rationale for bioenergetics based therapies. Aging Dis. 7:201–214. 2016. View Article : Google Scholar : PubMed/NCBI
14	Haddad D and Nakamura K: Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett. 589:3702–3713. 2005. View Article : Google Scholar
15	Rajasekaran A, Venkatasubramanian G, Berk M and Debnath M: Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neurosci Biobehav Rev. 48:10–21. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zanger UM and Schwab M: Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138:103–141. 2013. View Article : Google Scholar : PubMed/NCBI
17	Laursen T, Jensen K and Møller BL: Conformational changes of the NADPH-dependent cytochrome P450 reductase in the course of electron transfer to cytochromes P450. Biochim Biophys Acta. 1814:132–138. 2011. View Article : Google Scholar : PubMed/NCBI
18	Coon MJ: Cytochrome P450: Nature's most versatile biological catalyst. Annu Rev Pharmacol Toxicol. 45:1–25. 2005. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Cheng D, Cheng R, Zhu X, Wan T, Liu J and Zhang R: Mechanisms of U87 astrocytoma cell uptake and trafficking of monomeric versus protofibril Alzheimer's disease amyloid-β proteins. PLoS One. 9:e999392014. View Article : Google Scholar : PubMed/NCBI
20	Deb S, Zhang JW and Gottschall PE: Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to beta-amyloid peptide. J Neurosci Res. 55:44–53. 1999. View Article : Google Scholar : PubMed/NCBI
21	Lai JC, Ananthakrishnan G, Jandhyam S, Dukhande VV, Bhushan A, Gokhale M, Daniels CK and Leung SW: Treatment of human astrocytoma U87 cells with silicon dioxide nanoparticles lowers their survival and alters their expression of mitochondrial and cell signaling proteins. Int J Nanomedicine. 5:715–723. 2010.PubMed/NCBI
22	Iyanagi T: Structure and function of NADPH-cytochrome P450 reductase and nitric oxide synthase reductase domain. Biochem Biophys Res Commun. 338:520–528. 2005. View Article : Google Scholar : PubMed/NCBI
23	O'Brien RJ and Wong PC: Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci. 34:185–204. 2011. View Article : Google Scholar : PubMed/NCBI
24	Hao J, Zhang W, Zhang P, Liu R, Liu L, Lei G, Su C, Miao J and Li Z: Abeta20-29 peptide blocking apoE/Abeta interaction reduces full-length Abeta42/40 fibril formation and cytotoxicity in vitro. Neuropeptides. 44:305–313. 2010. View Article : Google Scholar : PubMed/NCBI
25	Jain P, Wadhwa PK and Jadhav HR: Reactive astrogliosis: Role in Alzheimer's disease. CNS Neurol Disord Drug Targets. 14:872–879. 2015. View Article : Google Scholar : PubMed/NCBI
26	Rodríguez JJ, Olabarria M, Chvatal A and Verkhratsky A: Astroglia in dementia and Alzheimer's disease. Cell Death Differ. 16:378–385. 2009. View Article : Google Scholar : PubMed/NCBI
27	Członkowska A and Kurkowska-Jastrzębska I: Inflammation and gliosis in neurological diseases-clinical implications. J Neuroimmunol. 231:78–85. 2011. View Article : Google Scholar : PubMed/NCBI
28	Agostinho P, Cunha RA and Oliveira C: Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des. 16:2766–2778. 2010. View Article : Google Scholar : PubMed/NCBI
29	Singh S and Joshi N: Astrocytes: Inexplicable cells in neurodegeneration. Int J Neurosci. 127:204–209. 2017. View Article : Google Scholar : PubMed/NCBI
30	Robel S and Sontheimer H: Glia as drivers of abnormal neuronal activity. Nat Neurosci. 19:28–33. 2016. View Article : Google Scholar : PubMed/NCBI
31	Pekny M, Pekna M, Messing A, Steinhäuser C, Lee JM, Parpura V, Hol EM, Sofroniew MV and Verkhratsky A: Astrocytes: A central element in neurological diseases. Acta Neuropathol. 131:323–345. 2016. View Article : Google Scholar : PubMed/NCBI
32	Yu D, Corbett B, Yan Y, Zhang GX, Reinhart P, Cho SJ and Chin J: Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging. 33:2942–2947. 2012. View Article : Google Scholar : PubMed/NCBI
33	Kvansakul M and Hinds MG: The Bcl-2 family: Structures, interactions and targets for drug discovery. Apoptosis. 20:136–150. 2015. View Article : Google Scholar : PubMed/NCBI
34	Obulesu M and Lakshmi MJ: Apoptosis in Alzheimer's disease: An understanding of the physiology, pathology and therapeutic avenues. Neurochem Res. 39:2301–2312. 2014. View Article : Google Scholar : PubMed/NCBI
35	Ajith TA and Padmajanair G: Mitochondrial Pharmaceutics: A new therapeutic strategy to ameliorate oxidative stress in Alzheimer's disease. Curr Aging Sci. 8:235–240. 2015. View Article : Google Scholar : PubMed/NCBI
36	Jonckheere AI, Smeitink JA and Rodenburg RJ: Mitochondrial ATP synthase: Architecture, function and pathology. J Inherit Metab Dis. 35:211–225. 2012. View Article : Google Scholar : PubMed/NCBI
37	Estabrook RW: Steroid hydroxylations: A paradigm for cytochrome P450 catalyzed mammalian monooxygenation reactions. Biochem Biophys Res Commun. 338:290–298. 2005. View Article : Google Scholar : PubMed/NCBI
38	Yao Y, Liu S, Wang Y, Yuan W, Ding X, Cheng T, Shen Q and Gu J: Suppression of cytochrome P450 reductase expression promotes astrocytosis in subventricular zone of adult mice. Neurosci Lett. 548:84–89. 2013. View Article : Google Scholar : PubMed/NCBI
39	Norris PJ, Hardwick JP and Emson PC: Localization of NADPH cytochrome P450 oxidoreductase in rat brain by immunohistochemistry and in situ hybridization and a comparison with the distribution of neuronal NADPH-diaphorase staining. Neuroscience. 61:331–350. 1994. View Article : Google Scholar : PubMed/NCBI